表紙
市場調查報告書

毛細胞白血病治療藥的全球市場:2019年∼2023年

Global Hairy Cell Leukemia Therapeutics Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 900616
出版日期 內容資訊 英文 129 Pages
訂單完成後即時交付
價格
毛細胞白血病治療藥的全球市場:2019年∼2023年 Global Hairy Cell Leukemia Therapeutics Market 2019-2023
出版日期: 2019年07月30日內容資訊: 英文 129 Pages
簡介

毛細胞白血病是一種罕見的,生長緩慢的白血病亞型,約佔白血病總數的2%。全球毛細胞白血病治療藥市場,2018年,化療市場區隔的市場佔有率變大,預計這個趨勢在預測期間也將持續。還有該市場,導致毛細胞白血病的有害物質暴露等因素,不斷增長的老年人口,戰略聯盟等成為毛細胞白血病成長促進因素,在預測期間內預計將以6%以上的年複合成長率擴大。可是,有限的患者群,化療藥的副作用,診斷困難等,可能妨礙在預測期間內毛細胞白血病治療產業的成長。

本報告提供全球毛細胞白血病治療藥市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各產品

  • 市場區隔:各產品
  • 各產品比較:市場規模及預測(2018年∼2023年)
  • 化療
  • 標靶治療
  • 市場機會:各產品

第7章 客戶形勢

第8章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 血液癌症的研究津貼增加
  • 新治療方法的登場
  • 特定醫藥品的指定

第12章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭方案

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Mylan NV
  • Pfizer Inc.

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR31795

About this market

Hairy cell leukemia is a rare, slow-growing subtype of leukemia, which accounts for about 2% of the total cases of leukemia. Technavio's hairy cell leukemia therapeutics analysis considers sales from both chemotherapies and targeted therapy. Our analysis also considers the sales of hairy cell leukemia therapeutics in North America, Europe, Asia, and the rest of the world (ROW). In 2018, the chemotherapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the increasing prevalence of leukemia, including hairy cell leukemia, will play a significant role in the chemotherapy segment to maintain its market position. Also, our global hairy cell leukemia therapeutics market report looks at factors such as increased exposure to hazardous substances leading to hairy cell leukemia, growing geriatric population, strategic alliances. However, limited patient pool, adverse effects of chemotherapy drugs, difficulty in diagnosis may hamper the growth of the hairy cell leukemia therapeutics industry over the forecast period.

Overview

Increasing exposure to hazardous substances leading to hairy cell leukemia

Exposure to such hazardous substances can happen due to various types of occupations such as farming, working in manufacturing plants dealing with hazardous chemicals and fumes, and working in coal mines, cement- and gravel-producing plants. Exposure to chemical fertilizers and pesticides is continuously increasing as the lack of nutrients in the soil has increased the use of fertilizers to provide required nutrients and to improve agriculture yields. Thus, to meet the food demand of the ever-increasing population, chemical fertilizers are increasingly used, which is expected to increase the prevalence of hairy cell leukemia which, in turn, will lead the expansion of the global hairy cell leukemia therapeutics market at a CAGR of over 6% during the forecast period.

Advent of novel therapies

The global hairy cell leukemia therapeutics market has been witnessing some advances in research since the beginning of the 21st century, which have led to the launch of a few novel therapies for the treatment of hairy cell leukemia and other hematologic malignancies. The strong prevalence of various types of blood cancer at the global level has necessitated the need for the development of advanced therapies, such as kinase inhibitors and gene therapies, to treat such conditions. Such advents of novel therapies are likely to offset the challenges posed by the adverse effects of chemotherapy drugs in the future: which will contribute to the growth of the market during the forecast period.

For the detailed list of factors that will drive the global hairy cell leukemia therapeutics market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global hairy cell leukemia therapeutics market is concentrated. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading hairy cell leukemia therapeutics manufacturers, that include AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan NV, and Pfizer Inc.

Also, the hairy cell leukemia therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Chemotherapy - Market size and forecast 2018-2023
  • Targeted therapy - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Increasing research grants for blood cancers
  • Advent of novel therapies
  • Special drug designations

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Mylan NV
  • Pfizer Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Chemotherapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Chemotherapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Targeted therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Targeted therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Patient assistance programs
  • Exhibit 25: Market opportunity by product
  • Exhibit 26: Customer landscape
  • Exhibit 27: Market share by geography 2018-2023 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: Top 3 countries in North America
  • Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Top 3 countries in Europe
  • Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: Proportion of geriatric population in Asia 2009 and 2018
  • Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Top 3 countries in Asia
  • Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 41: Top 3 countries in ROW
  • Exhibit 42: Key leading countries
  • Exhibit 43: Market opportunity
  • Exhibit 44: Growth in geriatric population 2014-2018 (%)
  • Exhibit 45: Side effects of chemotherapy drugs used for treatment of hairy cell leukemia
  • Exhibit 46: Impact of drivers and challenges
  • Exhibit 47: Drug designations
  • Exhibit 48: Vendor landscape
  • Exhibit 49: Landscape disruption
  • Exhibit 50: Vendors covered
  • Exhibit 51: Vendor classification
  • Exhibit 52: Market positioning of vendors
  • Exhibit 53: AstraZeneca Plc - Vendor overview
  • Exhibit 54: AstraZeneca Plc - Business segments
  • Exhibit 55: AstraZeneca Plc - Organizational developments
  • Exhibit 56: AstraZeneca Plc - Geographic focus
  • Exhibit 57: AstraZeneca Plc - Key offerings
  • Exhibit 58: AstraZeneca Plc - Key customers
  • Exhibit 59: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 60: F. Hoffmann-La Roche Ltd. - Product segments
  • Exhibit 61: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 62: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 63: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 64: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 65: F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 66: Merck & Co. Inc. - Vendor overview
  • Exhibit 67: Merck & Co. Inc. - Business segments
  • Exhibit 68: Merck & Co. Inc. - Organizational developments
  • Exhibit 69: Merck & Co. Inc. - Geographic focus
  • Exhibit 70: Merck & Co. Inc. - Segment focus
  • Exhibit 71: Merck & Co. Inc. - Key offerings
  • Exhibit 72: Merck & Co. Inc. - Key customers
  • Exhibit 73: Mylan NV - Vendor overview
  • Exhibit 74: Mylan NV - Product segments
  • Exhibit 75: Mylan NV - Organizational developments
  • Exhibit 76: Mylan NV - Geographic focus
  • Exhibit 77: Mylan NV - Segment focus
  • Exhibit 78: Mylan NV - Key offerings
  • Exhibit 79: Mylan NV - Key customers
  • Exhibit 80: Pfizer Inc. - Vendor overview
  • Exhibit 81: Pfizer Inc. - Business segments
  • Exhibit 82: Pfizer Inc. - Organizational developments
  • Exhibit 83: Pfizer Inc. - Geographic focus
  • Exhibit 84: Pfizer Inc. - Segment focus
  • Exhibit 85: Pfizer Inc. - Key offerings
  • Exhibit 86: Pfizer Inc. - Key customers
  • Exhibit 87: Validation techniques employed for market sizing
  • Exhibit 88: Definition of market positioning of vendors